News & Media
Zemcelpro® (dorocubicel) positive results in high- and very high-risk blood cancers to be reported at the EBMT 2026 Annual Meeting
Zemcelpro® (dorocubicel) achieved remarkable and clinically meaningful survival results in patients with high- and very high-risk acute leukemias and myelodysplastic syndromes Topline results from two Phase 2 studies to be presented on March 23, 2026 at the EBMT...
Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, February 16, 2026 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic...
Zemcelpro® (UM171 Cell Therapy) improved outcomes compared with common graft sources: European real-world evidence
MONTREAL, December 19, 2025 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics, announced the publication in the journal Transplantation and Cell...
Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells
Zemcelpro® is conditionally authorized by the European Commission for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is...
Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells
– If approved, Zemcelpro® is expected to: increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromes be the first and only therapy in the...
ExCellThera Announces International Non-proprietary Name and New Orphan Drug Designation for UM171 Cell Therapy
- UM171 Cell Therapy has been granted an International Nonproprietary Name (INN) of “dorocubicel” on the INN Recommended List issued by the World Health Organization (WHO) - The U.S. Food and Drug Administration (FDA) has granted UM171 Cell Therapy (INN-dorocubicel)...
ExCellThera announces new UM171 data to be presented at ASH 2023
MONTREAL, November 3, 2023 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and fitness, announced today several UM171 presentations, including an oral session on new data from Phase 2 studies of investigational UM171 cell therapy in...
UM171-Expanded Cell Therapy improves outcomes compared with other graft sources: Real-world evidence
MONTREAL, August 8, 2023 — Cordex Biologics Inc., an ExCellThera Company, announced today the recent publication in Blood Advances of results from a safety and efficacy retrospective analysis …